Proton Pump Inhibitors

    Want more claimants? Fill out the form to get free info.
    By submitting this form, I consent that I may be contacted by email and/or phone (including a wireless number) using automated technology, by Adwire Media and/or third-party partners. If I have provided my cell number I also acknowledge that I may be contacted via text message. Message and data rates may apply. My consent is not a requirement for receipt of services.*

    PPI Criteria

    The criteria below is a list of standard filters. We can customize the criteria based on your requirements.
    • Took one of the following medications
      • Prilosec
      • Nexium
      • Prevacid
      • Zegerid
      • Yosprala
      • Dexilent
      • Aciphex
      • Protonix
      • Vimovo
    • Suffered from any of the following injuries
      • Esophageal cancer
      • Liver cancer
      • Stomach cancer
    • No legal representation

    PPI Background Information


    A Stanford Medicine data mining study linked heartburn drugs to an increase risk of heart attack and Chronic Kidney Disease (CKD). PPIs have also been linked to acute kidney injuries, acute interstitial nephritis, and kidney or renal failure. Researchers found that people who take the medication to suppress the release of stomach acid are 16 percent to 21 percent more likely to suffer myocardial infarction.

    MDL 2789

    District of New Jersey, Judge Claire C. Cecchi. (On June 27, 2018 defendants agreed to toll SOLs to January 31, 2019 for federal claims and

    May 31, 2018 for state court cases to provide plaintiffs additional time to investigate and review claims before actually filing suit. First bellwether cases are planned for 2020.)


    AstraZeneca, Pfizer, Proctor & Gamble, Takeda Pharmaceuticals, Novartis


    Prilosec, Prevacid, Nexium, Dexilant, Protonix, AcipHex, Vimovo, Zegarid


    February 2016 – A new study published in the February 2016 issue of JAMA indicated a 20-50% increase in occurrence of CKD over baselines.

    • More than 100 million prescriptions filled annually in US.
    • Over 20 million users in the U.S., which is around one out of every 14 people. PPI’s have global annual sales of over $14 Billion a annually.


    2017 study finds that PPI’s were linked to an increased risk of kidney disease and kidney failure, even in persons who did not experience an acute kidney injury (AKI) first. At least three recent studies have found that people on long-term PPI “maintenance therapy” were at three times the risk of developing gastric cancer.


    We welcome you to contact Mass Torts USA for more information
    about our products and services.